COMP <GO>
TECH vs ABBV // OPERATING MARGIN
Bio-Techne Corp (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TECH 3
— ABBV 12
▲ OPERATING MARGIN LEADER: ABBV
LAST: $72.66 (-0.07%) • MKT CAP: $11.40B
operating-margins
8.40%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
operating-margins
24.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TECH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TECH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.80% | 70.20% | -5.40 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.40% | 29.00% | -25.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.3x | 33.3x | +58.00 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 2.25% | 3.47% | -1.22 | ABBV | /fcf-yield <GO> |
| Operating Margin ACTIVE | 8.40% | 24.60% | -16.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 6.00% | 6.90% | -0.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 8.60% | -3.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 2.27% | -1.83 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.12 | 5.33 | +1.79 | TECH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TECH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.40% | -0.90 | TECH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.2 | 72.8 | -15.58 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.15 | -0.27 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 113.1x | +26.90 | ABBV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.40B | $513.86B | -$502.46B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TECH REV | ABBV REV | TECH GROSS % | ABBV GROSS % | TECH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.22B | $61.16B | 64.8% | 70.2% | $256.6M | $17.82B |
| FY 2024 | $1.16B | $56.33B | 66.4% | 70.0% | $236.1M | $17.83B |
| FY 2023 | $1.14B | $54.32B | 44.0% | 44.0% | $203.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TECH // BETA 0.88
ABBV // BETA 1.15